Is Pharma Research Doing Enough for Diabetes?

With prediabetes and type 2 on the rise in the U.S., are pharma companies doing enough to develop new treatments? Harvard researchers argue that companies are doing less R&D into diabetes drugs than would be expected given the prevalence of the disease, and suggest FDA requirements to determine the cardiovascular safety of new drugs may be a major factor. Read more

Posted in Type II Drugs